AU2020268329B2 — Oxymetazoline compositions and methods for treating ocular disorders
Assigned to RVL Pharmaceuticals Inc · Expires 2026-01-15 · 0y expired
What this patent protects
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long-term storage. The present disclosure is also directed to compositions comprising oxymetazoline and methods of treating various eye disorders …
USPTO Abstract
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long-term storage. The present disclosure is also directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.